ANRO news

Latest 1 stories · newest Nov 10, 2026

ANRO

Venture-backed biotech boosts cash runway to fund ALTO-207 Phase 3 trials

Alto Neuroscience completed a $100 million financing, extending its cash runway to 2030, while confirming topline data is on track for 2H 2027. The company also plans to conduct parallel Phase 3 monotherapy trials to support a broader label.

Offering Nov 10, 2026 sentiment +0.30 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same ANRO feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/ANRO/newsSTART FREE